Risk of Changes to or Termination of Partnerships with Other Companies
First written in FY2020. 5 of 10 entries say "Materialised", first in FY2021-Q3. Latest entry: 2026-07-31.
Ono Pharmaceutical moved to the "Worse" side of this theme in 2021, 2 years before the typical company in this theme (2023).
The whole theme swung hardest in 2020: 8 of 42 companies on the "Worse" side.
0 other companies' latest entry also says "Cited as achieved".
- 2026-07-31Cited as achievedEarnings
「Following the termination of the co-promotion agreement with AstraZeneca for Farxiga tablets, no further sales of Farxiga tablets were recognized (¥25.1 billion in the same period of the previous year).」
The disappearance of Farxiga sales following the end of the co-promotion agreement was reflected in first-quarter sales results. - FY2026MaterialisedAnnual report
「The co-promotion agreement with AstraZeneca plc (United Kingdom) for dapagliflozin ended in March 2026.」
The termination of a co-promotion agreement with another company occurred, changing the business relationship relating to the marketing rights for Forxiga. - FY2025-H1MaterialisedAnnual report
「In October this year, we decided for strategic reasons not to exercise the option under the asset acquisition agreement with an exclusive option relating to itolizumab, which we entered into with US-based Equillium in December 2022.」
The partnership terms with Equillium regarding the option on itolizumab actually changed when we decided not to exercise the option for strategic reasons. - FY2022MaterialisedAnnual report
「For the BTK inhibitor ONO-4059, the company out-licensed it to US-based Gilead in 2014. In addition to the rights to develop and commercialize it in the oncology field, which had already been returned, the corresponding rights outside the oncology field were returned during the fiscal year.」
Under the ONO-4059 licensing agreement with Gilead, the rights in non-oncology fields were returned following the oncology rights, resulting in a further change and reduction in the scope of the partnership. - FY2022-Q3MaterialisedAnnual report
「* Regarding ONO-4059, the company out-licensed it to US-based Gilead in 2014, but the rights outside the oncology field within Gilead's territory were also returned. The rights in the oncology field had already been returned.」
Following the oncology rights, the rights outside oncology for ONO-4059 licensed to Gilead were also returned, resulting in a further change to the partnership terms. - FY2021-Q3MaterialisedAnnual report
「* Regarding ONO-4059, the company out-licensed it to US-based Gilead in 2014, but the rights in the oncology field within Gilead's territory were returned. Gilead continues to hold the rights outside the oncology field.」
The terms of a partnership have actually changed following the return of the oncology rights in Gilead’s territory by Gilead, the licensee. - FY2020First statedAnnual report
「Our Group enters into partnerships with other companies in various forms, including joint research, joint development, in- and out-licensing of development-stage products, and co-promotion. If the terms agreed with a partner are changed or terminated for any reason, our Group’s operating results and financial position may be affected.」
The risk that the terms of various partnerships with other companies may be changed or terminated has been listed as a standalone item for the first time.